11. Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor. (8th May 2019) Authors: Gooderham, M.; Elewski, B.E.; Pariser, D.M.; Sofen, H.; Mendelsohn, A.M.; Rozzo, S.J.; Li, Q. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 10(2019) Page Start: e350 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. OP0079 Ustekinumab is Effective in Inhibiting Radiographic Progression in Patients with Active Psoriatic Arthritis: Integrated Data Analysis of Two Phase 3, Randomized, Placebo-Controlled Studies. (10th June 2014) Authors: McInnes, I.; Ritchlin, C.; Rahman, P.; Puig, L.; Gottlieb, A.; Song, M.; Randazzo, B.; Li, S.; Wang, Y.; Mendelsohn, A.M.; Kavanaugh, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. OP0158 Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled psummit I study. (23rd January 2014) Authors: McInnes, I.B.; Kavanaugh, A.; Gottlieb, A.B.; Puig, L.; Rahman, P.; Ritchlin, C.; Li, S.; Wang, Y.; Mendelsohn, A.M.; Doyle, M.K. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study. (9th June 2015) Authors: Kavanaugh, A.; Puig, L.; Gottlieb, A.B.; Ritchlin, C.; You, Y.; Wang, Y.; Mendelsohn, A.M.; Song, M.; Rahman, P.; McInnes, I. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Outcomes of pregnancies from the tildrakizumab phase I–III clinical development programme. (1st July 2020) Authors: Haycraft, K.; DiRuggiero, D.; Rozzo, S.J.; Mendelsohn, A.M.; Bhutani, T. Journal: British journal of dermatology Issue: Volume 183:Number 1(2020) Page Start: 184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Outcomes of pregnancies from the tildrakizumab phase I–III clinical development programme. (29th March 2020) Authors: Haycraft, K.; DiRuggiero, D.; Rozzo, S.J.; Mendelsohn, A.M.; Bhutani, T. Journal: British journal of dermatology Issue: Volume 183:Number 1(2020) Page Start: 184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis. (12th June 2018) Authors: Crowley, J.; Leonardi, C.; Sturgill-Koszycki, S.; Menter, A.; Mendelsohn, A.M.; Li, Q.; Cichanowitz, N.; La Rosa, C. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1020 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. SAT0396 Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 2-Year Results from A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study. (10th June 2014) Authors: Kavanaugh, A.; Puig, L.; Gottlieb, A.; Ritchlin, C.; Li, S.; Wang, Y.; Mendelsohn, A.M.; Song, M.; Rahman, P.; McInnes, I. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. SAT0563 Long Term Improvements in Physical Function are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients. (9th June 2015) Authors: Kavanaugh, A.; Puig, L.; Gottlieb, A.B.; Ritchlin, C.; Li, S.; You, Y.; Mendelsohn, A.M.; Song, M.; Rahman, P.; McInnes, I. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 864 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials. (12th June 2018) Authors: Gooderham, M.; Elewski, B.E.; Pariser, D.M.; Sofen, H.; Mendelsohn, A.M.; Cichanowitz, N.; Li, Q.; La Rosa, C. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗